ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -18 مورد

Ibrutinib: Drug information

Ibrutinib: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Ibrutinib: Patient drug information" and "Ibrutinib: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Imbruvica
Brand Names: Canada
  • Imbruvica
Pharmacologic Category
  • Antineoplastic Agent;
  • Antineoplastic Agent, Bruton Tyrosine Kinase Inhibitor;
  • Antineoplastic Agent, Tyrosine Kinase Inhibitor
Dosing: Adult

Dosage guidance:

Safety: Evaluate the risks and benefits of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.

Clinical considerations: Consider antimicrobial prophylaxis (according to standard of care) in patients at risk for opportunistic infection. Patients should maintain adequate hydration to prevent dehydration in the event diarrhea occurs.

Chronic lymphocytic leukemia/small lymphocytic lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma (including chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion): Oral: 420 mg once daily (either as monotherapy, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab); continue until disease progression or unacceptable toxicity (Ref).

F ixed duration of treatment in previously untreated disease (off-label combination): Oral: 420 mg once daily on days 1 to 28 every 28 days (as a single agent) for 3 cycles, followed by 420 mg once daily on days 1 to 28 every 28 days (in combination with venetoclax [venetoclax is ramped up in cycle 4]) for an addition 12 cycles, for a total of 15 ibrutinib cycles (Ref). In one study, patients who completed 15 cycles (3 lead in cycles plus 12 combination cycles) were administered 1 additional cycle during which minimal residual disease status and tumor response were assessed (Ref).

Graft-versus-host disease, chronic, refractory

Graft-versus-host disease, chronic, refractory: Oral: 420 mg once daily; continue until chronic graft-versus-host disease (cGVHD) disease progression, recurrence of underlying malignancy, or unacceptable toxicity (Ref). When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.

Mantle cell lymphoma, relapsed or refractory

Mantle cell lymphoma, relapsed or refractory (alternative agent) (off-label use): Oral: 560 mg once daily; continue until disease progression or unacceptable toxicity (Ref).

Waldenström macroglobulinemia

Waldenström macroglobulinemia: Oral: 420 mg once daily (either as monotherapy or in combination with rituximab); continue until disease progression or unacceptable toxicity (Ref).

Missed doses: If a dose is not administered at the scheduled time, it may be administered as soon as possible on the same day; return to normal schedule the following day. Do not administer extra doses to make up for the missed dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: There have been reports of tumor lysis syndrome secondary to ibrutinib treatment in patients with underlying kidney dysfunction (Ref).

Altered kidney function:

CrCl ≥25 mL/minute: No dosage adjustment necessary (Ref).

CrCl <25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, <10% of ibrutinib is excreted by the kidneys (Ref); therefore, no dosage adjustment likely to be necessary. A single case report describes the successful use of ibrutinib in a patient with severe kidney impairment (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

Oral: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzed (Ref): Oral: Based on ibrutinib pharmacokinetic characteristics and case reports describing the successful use of ibrutinib in patients on hemodialysis, no dosage adjustment likely to be necessary (Ref).

Peritoneal dialysis: Oral: There are no data describing ibrutinib use in patients on peritoneal dialysis (has not been studied); however, no dosage adjustment likely to be necessary (Ref).

CRRT: Oral: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: No dosage adjustment necessary (Ref).

Dosing: Liver Impairment: Adult

Hepatic impairment prior to treatment initiation:

B-cell malignancies:

Mild impairment (Child-Turcotte-Pugh class A): Reduce dose to 140 mg once daily. Monitor more frequently for toxicities; may require treatment interruption.

Moderate impairment (Child-Turcotte-Pugh class B): Reduce dose to 70 mg once daily. Monitor more frequently for toxicities; may require treatment interruption.

Severe impairment (Child-Turcotte-Pugh class C): Avoid ibrutinib use.

Chronic graft-versus-host disease:

Total bilirubin >1.5 to 3 times ULN (unless of nonhepatic origin or due to Gilbert syndrome): Reduce dose to 140 mg once daily.

Total bilirubin >3 times ULN (unless of nonhepatic origin or due to Gilbert syndrome): Avoid ibrutinib use.

Acute hepatotoxicity during treatment: If drug-induced liver injury is suspected, withhold ibrutinib; discontinue ibrutinib if drug-induced liver injury is confirmed.

Dosing: Adjustment for Toxicity: Adult

Recommended ibrutinib dosage modifications for adverse reactions following improvement to grade 1 or baseline (recovery):

Ibrutinib Dose Modification for Adverse Reactions

Adverse reaction

Occurrence

Chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic graft-versus-host disease, and Waldenström macroglobulinemia

(Initial dose: 420 mg once daily)

a For other grade 4 nonhematologic toxicities, evaluate risks versus benefits prior to resuming ibrutinib.

Cardiac arrhythmias: Grade 3

First occurrence

Restart at 280 mg once daily (after assessment of risks vs benefits).

Second occurrence

Discontinue ibrutinib.

Cardiac arrhythmias: Grade 4

First occurrence

Discontinue ibrutinib.

Heart failure: Grade 2

First occurrence

Restart at 280 mg once daily (after assessment of risks vs benefits).

Second occurrence

Restart at 140 mg once daily (after assessment of risks vs benefits).

Third occurrence

Discontinue ibrutinib.

Heart failure: Grade 3 or 4

First occurrence

Discontinue ibrutinib.

Hypertension

Any

Initiate or adjust antihypertensive therapy as appropriate. If ≥ grade 3 hypertension occurs, follow dosage modifications below for other grade 3 or 4 nonhematologic toxicities.

Infection

Evaluate and manage appropriately.

Tumor lysis syndrome

Manage appropriately.

Other toxicities:

  • Other grade 3 or 4 nonhematological toxicitiesa

  • Grade 3 or 4 neutropenia with infection or fever

  • Grade 4 hematological toxicities

First occurrence

Restart at 280 mg once daily.

Second occurrence

Restart at 140 mg once daily.

Third occurrence

Discontinue ibrutinib.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Ibrutinib: Pediatric drug information")

Dosage guidance:

Dosing: Pediatric dosing in both mg/m2 and mg (fixed dose); use caution during dose calculations. Consider antimicrobial prophylaxis (according to standard of care) in patients at risk for opportunistic infection. Evaluate the risks and benefits of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.

Graft-versus-host disease, chronic, refractory

Graft-versus-host disease, chronic (cGVHD), refractory: Note: Continue ibrutinib therapy until cGVHD disease progression, recurrence of underlying malignancy, or unacceptable toxicity. When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.

Children <12 years:

BSA-directed dosing: Oral: 240 mg/m2 once daily; maximum dose: 420 mg/dose.

BSA-banded dosing (fixed-dosing): Oral:

BSA-Banded Dosing for Children <12 Years of Age

BSA (m2 )

Oral Suspension (70 mg/mL) Daily Dose (mg)

Capsule/Tablet Daily Dose (mg)

>0.3 to 0.4 m2

84 mg

>0.4 to 0.5 m2

105 mg

>0.5 to 0.6 m2

133 mg

>0.6 to 0.7 m2

154 mg

>0.7 to 0.8 m2

182 mg

210 mg

>0.8 to 0.9 m2

203 mg

210 mg

>0.9 to 1 m2

231 mg

210 mg

>1 to 1.1 m2

252 mg

280 mg

>1.1 to 1.2 m2

280 mg

280 mg

>1.2 to 1.3 m2

301 mg

280 mg

>1.3 to 1.4 m2

322 mg

350 mg

>1.4 to 1.5 m2

350 mg

350 mg

>1.5 to 1.6 m2

371 mg

350 mg

>1.6 m2

420 mg

420 mg

Children ≥12 years and Adolescents: Oral: 420 mg once daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing adjustment for toxicity:

Note: Pediatric dosing is in both mg/m2and mg; please review dosing units closely in table.

Children and Adolescents: Oral:

Ibrutinib Dose Modification for Adverse Reactions

Adverse Reaction

Occurrence

Ages 1 to <12 Years

(Based on Starting Dose ~240 mg/m2)

Age ≥12 Years

(Starting Dose: 420 mg)

a For other grade 4 nonhematologic toxicities, evaluate risks versus benefits prior to resuming ibrutinib.

Cardiac arrhythmias: Grade 3

First

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 mg/m2 once daily (after assessment of risks vs benefits).

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily (after assessment of risks vs benefits).

Second

Discontinue ibrutinib.

Discontinue ibrutinib.

Cardiac arrhythmias: Grade 4

First

Discontinue ibrutinib.

Discontinue ibrutinib.

Heart failure: Grade 2

First

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 mg/m2 once daily (after assessment of risks vs benefits).

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily (after assessment of risks vs benefits).

Second

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 80 mg/m2 once daily (after assessment of risks vs benefits).

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 140 mg once daily (after assessment of risks vs benefits).

Third

Discontinue ibrutinib.

Discontinue ibrutinib.

Heart failure: Grade 3 or 4

First

Discontinue ibrutinib.

Discontinue ibrutinib.

Hypertension

Any

Initiate or adjust antihypertensive therapy as appropriate. If ≥ grade 3 hypertension occurs, follow dosage modifications below for other grade 3 or 4 nonhematologic toxicities.

Other toxicities:

• Other grade 3 or 4 nonhematological toxicitiesa

• Grade 3 or 4 neutropenia with infection or fever

• Grade 4 hematological toxicities

First

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 mg/m2 once daily (after assessment of risks vs benefits).

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily.

Second

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 80 mg/m2 once daily (after assessment of risks vs benefits).

Hold dose until improved to Grade 1 or baseline (recovery). Restart at 140 mg once daily.

Third

Discontinue ibrutinib.

Discontinue ibrutinib.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents: Oral:

CrCl ≥25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, renal excretion is minimal and drug exposure is not altered in patients with mild to moderate impairment.

CrCl <25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

End-stage renal disease requiring dialysis: There are no dosage adjustments provided in the manufacturer's labeling (no data available).

Dosing: Liver Impairment: Pediatric

Baseline liver impairment:

Total bilirubin >1.5 to 3 times ULN (unless nonhepatic origin or Gilbert syndrome):

Children <12 years: Oral: 80 mg/m2once daily.

Children ≥12 years and Adolescents: Oral: 140 mg once daily.

Total bilirubin >3 times ULN (unless nonhepatic origin or Gilbert syndrome): Children and Adolescents: Avoid use.

Liver impairment during therapy: Children and Adolescents: If drug-induced liver injury is suspected, withhold ibrutinib; discontinue ibrutinib if drug-induced liver injury is confirmed.

Adverse Reactions (Significant): Considerations
Cardiac effects

Serious (and some fatal) cardiac arrhythmias and heart failure have occurred with ibrutinib, including ≥ grade 3 atrial fibrillation, atrial flutter, heart failure, and ventricular tachyarrhythmias. In an analysis utilizing the international pharmacovigilance database, ibrutinib was associated with higher reporting of cardiovascular adverse events, including heart failure, supraventricular cardiac arrhythmia, ventricular arrhythmia, cardiac conduction disorder, hypertension, and CNS hemorrhagic or ischemic events (Ref). Events have occurred in patients with and without preexisting cardiac risk factors.

Mechanism: Heart failure: May be caused by off-target blockade of HER2 and/or phosphoinositide 3-kinase-protein kinase B (PI3K–AKT) pathways. Supraventricular arrhythmias: May occur due to blockade of PI3K-AKT pathway, leading to activation of the late sodium current (INa-L) in atrial cells. Ventricular arrhythmias: Not clearly established; does not appear to be caused by QTc prolongation (Ref).

Onset: Varied; Heart failure: Median ~2 months (interquartile range: ~3 weeks to 5 months). Supraventricular arrhythmias: Median ~2.5 months (interquartile range: ~1 to 6.5 months). Ventricular arrhythmias: Median ~2 months (interquartile range: ~1 to 5 months) (Ref).

Risk factors:

• Older age (>70 years) (Ref)

• Males (Ref)

• History of cardiac arrhythmia (Ref)

• Hypertension (Ref)

• Preexisting cardiac disease (Ref)

• Diabetes mellitus

• Acute infections

• Concurrent cardiotoxic agents

Hematologic effects & infections

Grade 3 and 4 neutropenia, thrombocytopenia, and anemia occurred during clinical studies in patients who received single-agent ibrutinib for B-cell malignancies. An increased risk of opportunistic infection, including pneumonia due to Pneumocystis jirovecii (PJP), have occurred in patients treated with ibrutinib. Lymphocytosis (≥50% increase from baseline) and leukostasis may occur upon therapy initiation. Some patients who developed lymphocytosis (lymphocytes >400,000/mcL) developed intracranial hemorrhage, lethargy, headache, and abnormal gait; however, some cases may have been associated with disease progression. Lymphocytosis resolves within 8 weeks (mantle cell lymphoma) or 14 weeks (chronic lymphocytic leukemia) (Ref).

Mechanism: Related to mechanism of action; inhibits B-cell function, increasing the risk for opportunistic infections, such as PJP (Ref). Lymphocytosis is caused by disruption of integrin-mediated adhesion and homing of malignant B-cells, leading to release from the lymphoid microenvironment into systemic circulation (Ref).

Onset: Pancytopenia: Varied; within the initial months after initiation. Lymphocytosis: Intermediate; within the first few weeks/first month of therapy (Ref).

Hemorrhage

Major hemorrhage (and some fatal) has occurred with therapy, including grade ≥3, serious, or any CNS events (eg, intracranial hemorrhage [including subdural hematoma]), gastrointestinal hemorrhage, hematuria, and postprocedural hemorrhage (Ref). Bleeding events of any grade, including mucocutaneous bleeding (eg, bruise, petechia), have also occurred (Ref).

Mechanism: Related to mechanism of action; ibrutinib has anti-platelet effects, likely mediated by targeting von Willebrand factor (vWF)-glycoprotein Ib and collagen-glycoprotein VI signal transduction (Ref).

Onset: Varied; often corresponding to thrombocytopenia. Median onset of CNS hemorrhagic events: ~2 months (interquartile range: ~3 weeks to 6 months) (Ref).

Risk factors:

• Concurrent anticoagulant and/or antiplatelet therapy

• Lower baseline Factor VIII and vWF activity levels (Ref)

Hepatotoxicity

Hepatotoxicity, including severe and fatal cases, has been reported with ibrutinib. Reported reactions include abnormal liver function tests, hepatic cirrhosis, and hepatic failure (Ref).

Mechanism: Not clearly established; interaction of the tyrosine kinase signaling cascades with mediators of hepatocyte integrity has been proposed (Ref).

Onset: Varied; range of 2 to 36 weeks has been reported (Ref).

Hypertension

Hypertension has been reported in patients treated with ibrutinib. Hypertension may require initiation of antihypertensive therapy or adjustment of existing antihypertensive regimen. New or worsening hypertension has been associated with a higher risk of subsequent major adverse cardiovascular events (Ref).

Mechanism: Not clearly established; may occur due to downregulation of nitric oxide formation and endothelial dysfunction. Another postulated mechanism is inhibition of phosphoinositide-3-protein kinase B (PI3K)-AKT pathway, including indirect downregulation of PI3K-p110α, leading to vascular tissue fibrosis and cellular remodeling (Ref).

Onset: Varied; median: ~5.5 months (interquartile range ~3 weeks to 9 months) (Ref).

Risk factors:

• Preexisting hypertension (Ref)

• Older age (Ref)

• Increased BMI (Ref)

• History of diabetes mellitus (Ref)

• Chronic lymphocytic leukemia (Ref)

• Concurrent anthracycline use (Ref)

• Concurrent CYP3A4 inhibitors (Ref)

Progressive multifocal encephalopathy

Progressive multifocal leukoencephalopathy is a rare and often fatal infection of the cerebrum caused by the John Cunningham (JC) virus. Patients present with rapidly progressive neurological symptoms including, but not limited to confusion, speech or gait disorders, and urinary incontinence (Ref). Diagnosis may be delayed due to lack of awareness (Ref).

Mechanism: Not clearly established; may be related to inhibition of B-cell function, allowing JC virus reactivation (Ref).

Onset: Varied; ranges from ~1 month to 2 years after initiation in case reports (Ref).

Risk factors:

• Concurrent use of other B-cell–depleting agents (eg, rituximab, brentuximab, fludarabine) (Ref)

• Chronic lymphocytic leukemia (Ref)

Second primary malignancies

Patients treated with Bruton's tyrosine kinase inhibitors (BTKi), including ibrutinib, have developed second primary malignant neoplasm, such as nonmelanoma skin carcinoma and other non-skin carcinoma (Ref).

Mechanism: Not clearly established; may be related to immune dysfunction due to BTK inhibition (Ref).

Onset: Varied; median time to diagnosis is 26 months (range: ~12 days to ≥7 years) after initiation (Ref).

Risk factors:

• Chronic lymphocytic leukemia (Ref)

• Smoking (Ref)

• Higher baseline platelet count (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for ibrutinib monotherapy in adults, unless otherwise noted.

>10%:

Cardiovascular: Hypertension (children, adolescents, adults: 11% to 16%; cumulative rate increased over time) (table 1), peripheral edema (12% to 22%), sinus tachycardia (children, adolescents, adults: 11%)

Ibrutinib: Adverse Reaction: Hypertension

Drug (Ibrutinib)

Comparator (Chlorambucil)

Population

Dose

Indication

Number of Patients (Ibrutinib)

Number of Patients (Chlorambucil)

11%

N/A

Children, adolescents, and adults

≥12 years: 420 mg orally once daily, 1 to 12 years: 240 mg/m2 orally once daily

Chronic graft-versus-host disease

47

N/A

16%

N/A

Adults

420 mg once daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

51

N/A

14%

1%

Adults

420 mg daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

135

132

14%

N/A

Adults

420 mg once daily

Waldenström macroglobulinemia and marginal zone lymphoma

94

N/A

Dermatologic: Pruritus (children, adolescents, adults: 13%), skin infection (children, adolescents, adults: 15% to 18%), skin rash (children, adolescents, adults: 12% to 25%)

Endocrine & metabolic: Hypokalemia (children, adolescents, adults: 12% to 15%)

Gastrointestinal: Abdominal pain (children, adolescents, adults: 13% to 23%), constipation (12% to 22%), decreased appetite (16%), diarrhea (children, adolescents, adults: 28% to 59%; grades ≥3: 2% to 10%), dyspepsia (11% to 12%), gastroesophageal reflux disease (12%), nausea (children, adolescents, adults: 19% to 26%; grades ≥3: 1% to 4%), stomatitis (children, adolescents, adults: 14% to 29%; grades ≥3: 1% to 9%), vomiting (children, adolescents, adults: 13% to 19%; grades ≥3: 2%)

Genitourinary: Urinary tract infection (10% to 12%)

Hematologic & oncologic: Anemia (children, adolescents, adults: ≥20%; grades 3/4: 3%), bruise (11% to 51%; grades ≥3: 1% to 2%), hemorrhage (children, adolescents, adults: 17% to 28%; including major hemorrhage, gastrointestinal hemorrhage, hematuria, postprocedural hemorrhage), hypogammaglobulinemia (children, adolescents, adults: 11%), lymphocytosis (66%), neutropenia (children, adolescents, adults: ≥30%; grades 3/4: 2% to 23%), (table 2) petechia (children, adolescents, adults: 13% to 16%), thrombocytopenia (children, adolescents, adults: ≥20%; grades 3/4: 1% to 8%) (table 3)

Ibrutinib: Adverse Reaction: Neutropenia

Drug (Ibrutinib)

Comparator

Population

Dose

Indication

Number of Patients (Ibrutinib)

Number of Patients (Comparator)

Grade 4: 3%

N/A

Children, adolescents, and adults

≥12 years: 420 mg orally once daily, 1 to 12 years: 240 mg/m2 orally once daily

Chronic graft-versus-host disease

47

N/A

Grade 4: 2%

N/A

Adults

420 mg once daily

Chronic graft-versus-host disease

42

N/A

Grade 4: 12%

N/A

Adults

420 mg once daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

51

N/A

Grade 4: 11%

Chlorambucil: 12%

Adults

420 mg daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

135

132

Grade 4: 8%

Ofatumumab: 8%

Adults

420 mg daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

195

191

Grade 4: 7%

N/A

Adults

420 mg once daily

Waldenström macroglobulinemia and marginal zone lymphoma

94

N/A

Grades 3/4: 23%

N/A

N/A

N/A

B-cell malignancies

645

N/A

Ibrutinib: Adverse Reaction: Thrombocytopenia

Drug (Ibrutinib)

Comparator

Population

Dose

Indication

Number of Patients (Ibrutinib)

Number of Patients (Comparator)

Grade 4: 8%

N/A

Adults

420 mg once daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

51

N/A

Grade 4: 4%

N/A

Adults

420 mg once daily

Waldenström macroglobulinemia and marginal zone lymphoma

94

N/A

Grade 4: 2%

Ofatumumab: 3%

Adults

420 mg daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

195

191

Grade 4: 1%

Chlorambucil: 3%

Adults

420 mg daily

Chronic lymphocytic leukemia/small lymphocytic lymphoma

135

132

Grades 3/4: 8%

N/A

N/A

N/A

B-cell malignancies

645

N/A

Hepatic: Increased serum alanine aminotransferase (children, adolescents, adults: 11%)

Infection: Infection (including bacterial infection, fungal infection, viral infection [reactivation of HBV]), sepsis (children, adolescents, adults: 10% to 11%)

Nervous system: Asthenia (14%), chills (12%), dizziness (11% to 20%), falling (17%), fatigue (18% to 57%), headache (children, adolescents, adults: 12% to 21%)

Neuromuscular & skeletal: Arthralgia (16% to 24%), muscle spasm (11% to 29%), musculoskeletal pain (children, adolescents, adults: 14% to 36%), osteonecrosis (children, adolescents, adults: 11%)

Ophthalmic: Blurred vision (≤13%), decreased visual acuity (≤11%), dry eye syndrome (17%), increased lacrimation (13%)

Respiratory: Cough (children, adolescents, adults: 13% to 22%), dyspnea (10% to 12%), oropharyngeal pain (14%), pneumonia (children, adolescents, adults: 12% to 23%), sinusitis (11% to 22%), upper respiratory tract infection (16% to 47%)

Miscellaneous: Fever (children, adolescents, adults: 12% to 30%)

1% to 10%:

Cardiovascular: Atrial fibrillation (≤8%) (table 4), atrial flutter (≤8%) (table 5), heart failure (2%) (table 6), ventricular tachyarrhythmia (1%; including ventricular arrhythmia, ventricular fibrillation, cardiac [ventricular] flutter, ventricular premature contractions, ventricular tachycardia) (table 7)

Ibrutinib: Adverse Reaction: Atrial Fibrillation

Drug (Ibrutinib)

Control

Number of Patients (Ibrutinib)

Number of Patients (Control)

Comments

8%

2%

1,157

958

Combined term with atrial flutter

Ibrutinib: Adverse Reaction: Atrial Flutter

Drug (Ibrutinib)

Control

Number of Patients (Ibrutinib)

Number of Patients (Control)

Comments

8%

2%

1,157

958

Combined term with atrial fibrillation

Ibrutinib: Adverse Reaction: Heart Failure

Drug (Ibrutinib)

Control

Number of Patients (Ibrutinib)

Number of Patients (Control)

2%

0.5%

1,157

958

Ibrutinib: Adverse Reaction: Ventricular Tachyarrhythmia

Drug (Ibrutinib)

Control

Number of Patients (Ibrutinib)

Number of Patients (Control)

1%

0.4%

1,157

958

Endocrine & metabolic: Weight loss (10%)

Hematologic & oncologic: Second primary malignant neoplasm (10%; grades ≥3: 2%; including carcinoma [non-skin] and skin carcinoma [nonmelanoma])

Nervous system: Cerebrovascular disease (1%; including cerebral ischemia, cerebrovascular accident, intracranial hemorrhage, ischemic stroke, subdural hematoma, transient ischemic attacks) (table 8)

Ibrutinib: Adverse Reaction: Cerebrovascular Disease

Drug (Ibrutinib)

Control

Number of Patients (Ibrutinib)

Number of Patients (Control)

1%

0.4%

1,157

958

Postmarketing:

Cardiovascular: Cardiac conduction disorder (Ref), cardiac tamponade (Ref), cardiomyopathy (Ref), heart block (Ref), sinoatrial arrest (Ref), supraventricular cardiac arrhythmia (Ref)

Dermatologic: Cellulitis (Ref), dermatologic disorder (neutrophilic dermatoses), ecthyma (Ref), lichenoid eruption (Ref), maculopapular rash (Ref), nail disease (including onychoclasis, onychomadesis, paronychia, pyogenic granuloma [periungual]) (Ref), pityriasis rosacea (Ref), pyoderma gangrenosum (Ref), Stevens-Johnson syndrome, urticaria

Endocrine & metabolic: Hyponatremia (Ref)

Hematologic & oncologic: Abnormal platelet aggregation (Ref), hemophagocytic lymphohistiocytosis (Ref), tumor lysis syndrome (Ref)

Hepatic: Hepatic cirrhosis, hepatic failure (Ref), hepatotoxicity (Ref)

Hypersensitivity: Anaphylactic shock, angioedema, hypersensitivity angiitis (lymphocytic vasculitis) (Ref)

Infection: Mucormycosis (Ref)

Nervous system: Peripheral neuropathy (Ref), progressive multifocal leukoencephalopathy (Ref)

Neuromuscular & skeletal: Panniculitis

Ophthalmic: Anterior chamber eye hemorrhage (hyphema) (Ref), cystoid macular edema (Ref), uveitis (Ref)

Renal: Acute kidney injury (including acute interstitial nephritis) (Ref), acute renal tubular disease (Ref), kidney failure

Respiratory: Hemothorax (Ref), interstitial lung disease, pneumonia due to Pneumocystis jirovecii (Ref), pneumonitis (Ref)

Miscellaneous: Serositis (Ref)

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Known hypersensitivity to ibrutinib or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• CNS effects: May cause dizziness, fatigue, and/or weakness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• GI toxicity: Diarrhea has been commonly observed; maintain adequate hydration.

Special populations:

• Older adults: Anemia (all grades), thrombocytopenia, pneumonia (≥ grade 3), hypertension, and atrial fibrillation occurred more frequently in patients ≥65 years of age.

• Patients undergoing surgery or procedures: Evaluate the risks and benefits of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.

• Waldenström macroglobulinemia: Hyperviscosity may require plasmapheresis prior to or during ibrutinib treatment in patients with Waldenström macroglobulinemia; adjustment of ibrutinib dose due to plasmapheresis is not necessary.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Adherence: A retrospective analysis of a phase 3 efficacy trial in previously treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma evaluated the effect of dose intensity on progression-free survival (PFS) and overall response rate (ORR). A higher dose intensity was associated with longer median PFS and a higher ORR; optimal outcomes were achieved in patients with sustained adherence to a 420 mg/day dosing schedule (Barr 2017).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Imbruvica: 70 mg, 140 mg

Suspension, Oral:

Imbruvica: 70 mg/mL (108 mL) [contains benzyl alcohol]

Tablet, Oral:

Imbruvica: 140 mg, 280 mg, 420 mg, 560 mg [DSC]

Generic Equivalent Available: US

No

Pricing: US

Capsules (Imbruvica Oral)

70 mg (per each): $725.68

140 mg (per each): $241.89

Suspension (Imbruvica Oral)

70 mg/mL (per mL): $120.95

Tablets (Imbruvica Oral)

140 mg (per each): $725.68

280 mg (per each): $725.68

420 mg (per each): $725.68

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Imbruvica: 140 mg

Suspension, Oral:

Imbruvica: 70 mg/mL (150 mL) [contains benzyl alcohol]

Administration: Adult

Oral:

Capsules and tablets: Administer with a glass of water at approximately the same time each day. Swallow capsules or tablets whole. Do not open, break, or chew capsules; do not cut, crush, or chew tablets. Maintain adequate hydration during treatment.

Based on an analysis of 3 pharmacokinetic studies, it is suggested that ibrutinib may be administered without regard to food (Ref).

Ibrutinib was administered via NG and percutaneous endoscopic gastrostomy tube (single case report) by opening the capsule contents and flushing the contents down the tube(s) with water (Ref).

When administering ibrutinib in combination with rituximab or obinutuzumab, consider administering ibrutinib prior to rituximab or obinutuzumab when given on the same day.

Suspension: Bottle is supplied with 2 reusable oral dosing syringes. Use only the oral dosing syringes that are supplied with ibrutinib suspension, do not use syringes for other patients or from other medications; do not use a household teaspoon (overdosage may occur). Shake well before use. Do not remove the bottle adapter. When measuring dose, remove air bubbles to ensure correct dose. Administer as soon as possible after withdrawing dose from bottle. Administer water after the ibrutinib suspension dose. Following administration, rinse oral syringe with water and let air-dry (do not use soap to clean; do not put in dishwasher). Refer to manufacturer’s instructions for more details.

Administration: Pediatric

Oral: Administer with a glass of water at approximately the same time each day. Maintain adequate hydration during treatment.

Capsules/tablets: Swallow capsules or tablets whole. Do not open, break, or chew capsules; do not cut, crush, or chew tablets. Based on an analysis of 3 pharmacokinetic studies in adults, it is suggested that ibrutinib may be administered without regard to food (Ref).

Administration via feeding tube: A single case report describes ibrutinib administration via NG and percutaneous endoscopic gastrostomy tube in an adult by opening the capsule contents and flushing the contents down the tube(s) with water (Ref).

Oral suspension: With first use, document 60 days from opening as the discard date on the container. Shake well before use; attached bottle adapter should not be removed and may be wiped with a disposable tissue; use provided oral syringes to measure dose (if air bubble[s], pull plunger back a bit and tap side of syringe to remove air bubbles); squirt dose along inside of mouth along cheek; follow dose with a glass of water. After use, rinse oral syringe with water only and let air dry; do not clean with soap or in the dishwasher.

Missed dose: Administer as soon as the missed dose is remembered on the same day; return to normal scheduling the following day. Do not take extra doses to make up for the missed dose.

Use: Labeled Indications

Chronic graft-versus-host disease, refractory: Treatment of chronic graft-versus-host disease in adults and pediatric patients ≥1 year of age after failure of ≥1 lines of systemic therapy.

Chronic lymphocytic leukemia/small lymphocytic lymphoma:

Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adults.

Treatment of CLL/SLL in adults with 17p deletion.

Waldenström macroglobulinemia: Treatment of Waldenström macroglobulinemia in adults.

Use: Off-Label: Adult

Mantle cell lymphoma, relapsed or refractory (alternative agent)

Medication Safety Issues
Sound-alike/look-alike issues:

Ibrutinib may be confused with acalabrutinib, avapritinib, Ibrance, ibritumomab, idelalisib, imatinib, ivosidenib, pirtobrutinib, zanubrutinib.

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

Metabolism/Transport Effects

Substrate of CYP2D6 (Minor), CYP3A4 (Major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Agents with Antiplatelet Effects: May increase adverse/toxic effects of Ibrutinib. Specifically, the risk of bleeding and hemorrhage may be increased. Risk C: Monitor

Androgens: Hypertension-Associated Agents may increase hypertensive effects of Androgens. Risk C: Monitor

Anticoagulants: May increase adverse/toxic effects of Ibrutinib. Specifically, the risks of bleeding and hemorrhage may be increased. Risk C: Monitor

Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of BCG Products. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Bitter Orange: May increase serum concentration of Ibrutinib. Risk X: Avoid

Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Miscellaneous Oncologic Agents) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor

COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Subunit). Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of Ibrutinib. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Ibrutinib. Risk X: Avoid

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Ibrutinib. Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions. Risk D: Consider Therapy Modification

CYP3A4 Inhibitors (Strong): May increase serum concentration of Ibrutinib. Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued. Risk X: Avoid

Dabigatran Etexilate: Ibrutinib may increase anticoagulant effects of Dabigatran Etexilate. Ibrutinib may increase serum concentration of Dabigatran Etexilate. Risk C: Monitor

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Digoxin: Ibrutinib may increase serum concentration of Digoxin. Risk C: Monitor

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Flaxseed Oil: May increase adverse/toxic effects of Ibrutinib. Specifically, the risk for bleeding events may be increased. Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Grapefruit Juice: May increase serum concentration of Ibrutinib. Risk X: Avoid

Icosapent Ethyl: May increase antiplatelet effects of Ibrutinib. Risk C: Monitor

Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Inebilizumab. Risk C: Monitor

Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider Therapy Modification

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Methotrexate: Ibrutinib may increase serum concentration of Methotrexate. Risk C: Monitor

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Mumps- Rubella- or Varicella-Containing Live Vaccines may increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ocrelizumab. Risk C: Monitor

Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ofatumumab. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Omega-3 Fatty Acids: May increase antiplatelet effects of Ibrutinib. Risk C: Monitor

Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Posaconazole: May increase serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with posaconazole. Dose recommendations depend on the indication for ibrutinib, age of the patient, and the posaconazole dose. See full Lexi Interact monograph for details. Risk D: Consider Therapy Modification

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Solriamfetol: May increase hypertensive effects of Hypertension-Associated Agents. Risk C: Monitor

Sphingosine 1-Phosphate (S1P) Receptor Modulators: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk C: Monitor

St John's Wort: May decrease serum concentration of Ibrutinib. Risk X: Avoid

Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Therapeutic Antiplatelets: May increase adverse/toxic effects of Ibrutinib. Specifically, the risks of bleeding and hemorrhage may be increased. Risk C: Monitor

Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ublituximab. Risk C: Monitor

Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider Therapy Modification

Vitamin E (Systemic): May increase antiplatelet effects of Ibrutinib. Risk C: Monitor

Voriconazole: May increase serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with voriconazole. Dose recommendations depend on the indication for ibrutinib, age of the patient, and the voriconazole dose. See full Lexi Interact monograph for details. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Food Interactions

Grapefruit and Seville oranges inhibit CYP3A (moderately or strongly) and may increase ibrutinib exposure. Management: Avoid grapefruit and Seville oranges during therapy.

Reproductive Considerations

Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 1 month after the last ibrutinib dose; patients with partners who could become pregnant should use effective contraception during treatment and for 1 month after the last ibrutinib dose.

Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to ibrutinib may cause fetal harm.

Breastfeeding Considerations

It is not known if ibrutinib is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last ibrutinib dose.

Dietary Considerations

Avoid grapefruit, grapefruit juice, and Seville oranges during therapy.

Monitoring Parameters

Monitor blood counts monthly or as clinically necessary; hepatic function (evaluate bilirubin and transaminases prior to treatment initiation and throughout treatment; monitor more frequently for LFT abnormalities and clinical signs/symptoms of hepatoxicity); renal function; uric acid levels as clinically necessary. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor BP. Evaluate cardiac history/function at baseline; monitor cardiac function and for cardiac arrhythmias as clinically indicated, and monitor for signs/symptoms of cardiac arrhythmias and/or heart failure; obtain further evaluation (ECG or echocardiogram) as clinically indicated in patients who develop signs/symptoms of arrhythmias. Assess baseline risk for tumor lysis syndrome. Monitor for sign/symptoms of bleeding, hepatotoxicity, infections/fever, progressive multifocal encephalopathy, tumor lysis syndrome, and/or second primary malignancies. Monitor for signs of leukostasis, particularly in patients experiencing a rapid increase in lymphocytes to >400,000/mcL. Monitor adherence.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as weekly home monitoring for initial 3 months), obtain ECG at each clinical visit, obtain a baseline echocardiography (transthoracic preferred) in high-risk patients; echocardiography is also recommended in all patients who develop atrial fibrillation (ESC [Lyon 2022]).

Mechanism of Action

Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an integral component of the B-cell receptor (BCR) and cytokine receptor pathways. Constitutive activation of B-cell receptor signaling is important for survival of malignant B-cells; BTK inhibition results in decreased malignant B-cell proliferation and survival.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Adults: Vd: 683 L; Vdss/F: ~10,000 L (Marostica 2015).

Bioavailability: Absolute bioavailability in fasted condition was 2.9% and doubled when combined with a meal. Administration with a high-fat, high-calorie meal (800 to 1,000 calories with ~50% of caloric content from fat) increased the Cmax by ~2- to 4-fold and the AUC 2-fold (compared with overnight fasting). Administration under fasting conditions resulted in exposure of ~60% compared to when administered either 30 minutes before or after a meal, or 2 hours after a high-fat meal (de Jong 2015).

Protein binding: ~97%.

Metabolism: Hepatic via CYP3A (major) and CYP2D6 (minor) to active metabolite PCI-45227.

Half-life elimination: Adults: 4 to 6 hours.

Time to peak: Adults: 1 to 2 hours (4 hours under fed conditions [de Jong 2015]).

Excretion: Feces (80%; 1% as unchanged drug); urine (<10%, as metabolites).

Clearance (apparent): Oral: Adults: 2,000 L/hour (fasted); 1,000 L/hour (fed).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: AUC was increased 2.7-, 8.2-, and 9.8-fold, respectively, (Cmax was increased 5.2-, 8.8-, and 7-fold, respectively) in subjects with mild (Child-Pugh class A), moderate (Child-Pugh class B), or severe (Child-Pugh class C) hepatic impairment compared with subjects with normal hepatic function in a single-dose hepatic impairment trial.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Ibrutix | Imbruvica;
  • (AR) Argentina: Binap | Brikatib | Brocabe | Brunitib | Ibruleu | Ibrutinex | Ibruvanza | Ibrux | Imbruvica | Plifosir | Vilanor;
  • (AT) Austria: Imbruvica;
  • (AU) Australia: Imbruvica;
  • (BD) Bangladesh: Ibrucent | Ibruxen;
  • (BE) Belgium: Imbruvica;
  • (BG) Bulgaria: Imbruvica;
  • (BR) Brazil: Imbruvica;
  • (CH) Switzerland: Imbruvica;
  • (CL) Chile: Imbruvica | Nibitik;
  • (CN) China: Imbruvica;
  • (CO) Colombia: Imbruvica;
  • (CZ) Czech Republic: Imbruvica;
  • (DE) Germany: Imbruvica;
  • (DO) Dominican Republic: Imbruvica;
  • (EC) Ecuador: Binap | Brocabe | Imbruvica;
  • (EE) Estonia: Imbruvica;
  • (EG) Egypt: Imbruvica;
  • (ES) Spain: Imbruvica;
  • (FI) Finland: Imbruvica;
  • (FR) France: Imbruvica;
  • (GB) United Kingdom: Imbruvica;
  • (GR) Greece: Imbruvica;
  • (HK) Hong Kong: Imbruvica;
  • (HR) Croatia: Imbruvica;
  • (HU) Hungary: Imbruvica;
  • (ID) Indonesia: Imbruvica;
  • (IE) Ireland: Imbruvica;
  • (IN) India: Bdbrut | Ibrunat | Imbruvica | Nitib;
  • (IT) Italy: Imbruvica;
  • (JP) Japan: Imbruvica;
  • (KE) Kenya: Notafol;
  • (KR) Korea, Republic of: Imbruvica;
  • (KW) Kuwait: Imbruvica;
  • (LB) Lebanon: Imbruvica;
  • (LT) Lithuania: Imbruvica;
  • (LV) Latvia: Imbruvica;
  • (MA) Morocco: Imbruvica;
  • (MX) Mexico: Imbruvica;
  • (MY) Malaysia: Imbruvica;
  • (NL) Netherlands: Imbruvica;
  • (NO) Norway: Imbruvica;
  • (NZ) New Zealand: Imbruvica;
  • (PE) Peru: Binap | Brocabe | Imbruvica | Vilanor;
  • (PH) Philippines: Imbruvica;
  • (PL) Poland: Imbruvica;
  • (PR) Puerto Rico: Imbruvica;
  • (PT) Portugal: Imbruvica;
  • (PY) Paraguay: Imbruvica;
  • (QA) Qatar: Imbruvica;
  • (RO) Romania: Imbruvica;
  • (RU) Russian Federation: Imbruvica;
  • (SA) Saudi Arabia: Dullarma | Imbruvica;
  • (SE) Sweden: Imbruvica;
  • (SG) Singapore: Imbruvica;
  • (SI) Slovenia: Imbruvica;
  • (SK) Slovakia: Imbruvica;
  • (TH) Thailand: Imbruvica;
  • (TN) Tunisia: Imbruvica;
  • (TR) Turkey: Imbruvica;
  • (TW) Taiwan: Imbruvica;
  • (UA) Ukraine: Imbruvika;
  • (UY) Uruguay: Imbruvica;
  • (ZA) South Africa: Imbruvica
  1. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940-1943. [PubMed 27503501]
  2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281 [PubMed 11487763]
  3. Alamri A, Alghamdi Y, Alghamdi A, Albogami DB, Shahada O, AlHarbi A. Ibrutinib-induced paronychia and periungual pyogenic granuloma. Cureus. 2022;14(12):e32943. doi:10.7759/cureus.32943 [PubMed 36712781]
  4. Aldecoa KAT, Macaraeg CSL, Dadlani A, Yadlapalli S. Spontaneous hyphema during ibrutinib treatment in a CLL patient. Case Rep Hematol. 2023;2023:1691996. doi:10.1155/2023/1691996 [PubMed 38130705]
  5. Ambinder AJ, Hambley B, Shanbhag S, Merrill SA. Ibrutinib-associated hemophagocytic lymphohistiocytosis: a case series from Johns Hopkins. Am J Hematol. 2019;94(11):E296-E299. doi:10.1002/ajh.25611 [PubMed 31400009]
  6. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400 [PubMed 27918725]
  7. Aw A, Hellman JM, Birner A, Davids MS. A complex case of ibrutinib treatment for a CLL patient on haemodialysis. Br J Haematol. 2018;181(6):854-857. doi:10.1111/bjh.14718 [PubMed 28508526]
  8. Barr PM, Brown JR, Hillmen O, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612-2615. doi:10.1182/blood-2016-12-737346 [PubMed 28373262]
  9. Ben-Avi R, Dori D, Chowers I. Cystoid macular edema secondary to ibrutinib. Am J Ophthalmol Case Rep. 2022;26:101436. doi:10.1016/j.ajoc.2022.101436 [PubMed 35243171]
  10. Bennett CL, Berger JR, Sartor O, et al. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018;180(2):301-304. doi:10.1111/bjh.14322 [PubMed 27649938]
  11. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  12. Bitar C, Sadeghian A, Sullivan L, Murina A. Ibrutinib-associated pityriasis rosea-like rash. JAAD Case Rep. 2017;4(1):55-57. doi:10.1016/j.jdcr.2017.06.035 [PubMed 29387749]
  13. Bohn M, Bravo-Ljubetic L, Lee RWJ, Petrushkin H. Ibrutinib-related uveitis: a report of two severe cases. Eur J Ophthalmol. 2022;32(4):NP94-NP97. doi:10.1177/11206721211001268 [PubMed 33719653]
  14. Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34(12):3197-3205. doi:10.1038/s41375-020-0987-6 [PubMed 32704159]
  15. Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-2437. doi:10.1056/NEJMoa1509388 [PubMed 26639149]
  16. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223. [PubMed 24881631]
  17. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. [PubMed 23782158]
  18. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  19. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211. doi:10.1016/S1470-2045(15)00465-9 [PubMed 26655421]
  20. de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75(5):907-916. doi:10.1007/s00280-015-2708-9 [PubMed 25724156]
  21. de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629-1639. doi:10.3324/haematol.2017.164103 [PubMed 28775119]
  22. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919-1928. doi:10.1182/blood.2019000840 [PubMed 31582362]
  23. Dimopoulos MA, Tedeschi A, Trotman J, et al; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410. doi:10.1056/NEJMoa1802917 [PubMed 29856685]
  24. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-778. doi:10.1016/S0140-6736(15)00667-4 [PubMed 26673811]
  25. Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  26. Eyre TA, Bishton MJ, McCulloch R, et al; Haemato-Oncology Task Force of the British Society for Haematology. Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline. Br J Haematol. 2024;204(1):108-126. doi:10.1111/bjh.19131 [PubMed 37880821]
  27. Filanovsky K, Shvidel L. Safety and efficacy of ibrutinib in a patient with severe renal impairment. Hematol Rep. 2017;9(3):7078. doi:10.4081/hr.2017.7078 [PubMed 29071051]
  28. Ghasoub R, Albattah A, Elazzazy S, et al. Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - case report and literature review. J Oncol Pharm Pract. 2020;26(2):487-491. doi:10.1177/1078155219856422 [PubMed 31216242]
  29. Hsiehchen D, Arasaratnam R, Raj K, Froehlich T, Anderson L. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. Oncology. 2018;95(5):319-322. doi:10.1159/000490617 [PubMed 30045034]
  30. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  31. Imbruvica (ibrutinib) [prescribing information]. South San Francisco, CA: Pharmacyclics LLC; December 2024.
  32. Imbruvica (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; March 2023.
  33. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  34. Jensen AB, Stausbøl-Grøn B, Riber-Hansen R, d'Amore F. Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstrom's macroglobulinemia and review of the literature. Dermatol Reports. 2017;9(1):6976. doi:10.4081/dr.2017.6976 [PubMed 28469834]
  35. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783-787. [PubMed 25138588]
  36. Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200006. Published May 13, 2022. Accessed May 26, 2023. [PubMed 38319255]
  37. Kidoguchi K, Kubato Y, Nishimura Y, Kizuka-Sano H, Kimura S. Ibrutinib-induced cardiac tamponade in chronic lymphocytic leukemia. Turk J Haematol. 2021;38(1):83-85. doi:10.4274/tjh.galenos.2020.2020.0446 [PubMed 33161683]
  38. Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JMI. Rare but serious: ibrutinib induced liver failure. Hemasphere. 2019;3(6):e307. doi:10.1097/HS9.0000000000000307 [PubMed 31976481]
  39. Kyi HH, Zayed Y, Al Hadidi S. Ibrutinib-induced cardiomyopathy. J Community Hosp Intern Med Perspect. 2019;9(1):50-52. doi:10.1080/20009666.2018.1555432 [PubMed 30788077]
  40. Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581-2584. [PubMed 28223277]
  41. Lipsky AH, Farooqui MZ, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571-1578. doi:10.3324/haematol.2015.126672 [PubMed 26430171]
  42. Lutz M, Schulze AB, Rebber E, et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat. 2017;49(2):548-552. doi:10.4143/crt.2016.110 [PubMed 27456945]
  43. Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
  44. Maddox JM, Majid M. Use of ibrutinib via nasogastric (NG) tube & percutaneous endoscopic gastrostomy (PEG) tube. Blood. 2016;128(22):5371 [abstract from 2016 American Society of Hematology annual meeting].
  45. Manohar S, Bansal A, Wanchoo R, Sakhiya V, Lucia S, Jhaveri KD. Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol. 2019;94(9):E223-E225. doi:10.1002/ajh.25546 [PubMed 31148235]
  46. Markóth C, File I, Szász R, Bidiga L, Balla J, Mátyus J. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021;43(1):335-339. doi:10.1080/0886022X.2021.1874985 [PubMed 33567947]
  47. Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75(1):111-121. [PubMed 25381051]
  48. Mathur K, Saini A, Ellenbogen KA, Shepard RK. Profound sinoatrial arrest associated with ibrutinib. Case Rep Oncol Med. 2017;2017:7304021. doi:10.1155/2017/7304021 [PubMed 29375920]
  49. Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016;127(8):1064-1067. [PubMed 26702066]
  50. Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-2250. doi:10.1182/blood-2017-07-793786 [PubMed 28924018]
  51. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56. doi:10.1016/S1470-2045(18)30788-5 [PubMed 30522969]
  52. Nandikolla AG, Derman O, Nautsch D, et al. Ibrutinib-induced severe liver injury. Clin Case Rep. 2017;5(6):735-738. doi:10.1002/ccr3.881 [PubMed 28588800]
  53. Nguyen TM, Amenta E, Chapman L, et al. Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature. Ther Adv Infect Dis. 2024;11:20499361241241199. doi:10.1177/20499361241241199 [PubMed 38545450]
  54. Ohtani T, Tani A, Namme Y, et al. Pharmacokinetics of ibrutinib in a patient with chronic lymphocytic leukemia on hemodialysis. Clin Nephrol. 2022;98(6):301-304. doi:10.5414/CN110859 [PubMed 36278298]
  55. Ozturk E, Erdogan Ozunal I. A rare side effect of ibrutinib: tumor lysis syndrome. Medeni Med J. 2021;36(2):176-179. doi:10.5222/MMJ.2021.56424 [PubMed 34239769]
  56. Reji M, Shah KK. A novel finding of lichenoid drug reaction from ibrutinib therapy. Cureus. 2022;14(2):e22433. doi:10.7759/cureus.22433 [PubMed 35371696]
  57. Rodriguez-Baeza D, Pérez-López E, Román-Curto C, Santos-Briz A. Cutaneous lymphocytic vasculitis due to ibrutinib therapy. Actas Dermosifiliogr. 2024;115(10):1073-1074. doi:10.1016/j.ad.2023.04.039 [PubMed 38307170]
  58. Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799-1803. doi:10.1038/s41375-018-0023-2 [PubMed 29572505]
  59. Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667-1678. doi:10.1016/j.jacc.2019.07.056 [PubMed 31558250]
  60. Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43(2):289-297. doi:10.1124/dmd.114.060061 [PubMed 25488930]
  61. Shaikh H, Khattab A, Faisal MS, et al. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract. 2019;25(5):1265-1270. doi:10.1177/1078155218788707 [PubMed 30045682]
  62. Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112-120. doi:10.1182/blood.2021014960 [PubMed 35427411]
  63. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443. doi:10.1056/NEJMoa1817073 [PubMed 31365801]
  64. Sławińska M, Barańska-Rybak W, Sobjanek M, Wilkowska A, Mital A, Nowicki R. Ibrutinib-induced pyoderma gangrenosum. Pol Arch Med Wewn. 2016;126(9):710-711. doi:10.20452/pamw.3578 [PubMed 27698335]
  65. Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-associated serositis in mantle cell lymphoma. Am J Respir Crit Care Med. 2019;199(12):e43-e44. doi:10.1164/rccm.201809-1738IM [PubMed 30802411]
  66. Tafesh ZH, Coleman M, Fulmer C, Nagler J. Severe hepatotoxicity due to ibrutinib with a review of published cases. Case Rep Gastroenterol. 2019;13(2):357-363. doi:10.1159/000502605 [PubMed 31607836]
  67. Titus-Rains KS, Brown JN, Hammond JM. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: a case series and review of the literature. J Oncol Pharm Pract. 2018;24(7):544-549. doi:10.1177/1078155217718617 [PubMed 28714377]
  68. Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565-575. doi:10.1200/JCO.20.00555 [PubMed 32931398]
  69. Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440. [PubMed 25853747]
  70. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  71. Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR. High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Rep. 2021;7(6):391-394. doi:10.1016/j.hrcr.2021.03.013 [PubMed 34194987]
  72. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739-745. doi:10.1182/blood-2015-03-635326 [PubMed 26059948]
  73. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853-3865. doi:10.1200/JCO.21.00807 [PubMed 34618601]
  74. Wong JSY, Sadullah S. Acute haemothorax secondary to ibrutinib: a case report. EJHaem. 2022;3(4):1365-1366. doi:10.1002/jha2.367 [PubMed 36467786]
  75. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-1817. [PubMed 24415539]
  76. Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Sci. 2021;112(7):2607-2624. doi:10.1111/cas.14933 [PubMed 33938097]
Topic 91587 Version 341.0